Calcitonin negative Medullary Thyroid Carcinoma: a challenging diagnosis or a medical dilemma?

[1] HAZARD JOHN B.(1959)MEDULLARY (SOLID) CARCINOMA OF THE THYROID—A CLINICOPATHOLOGIC ENTITY* The Journal of Clinical Endocrinology & Metabolism 19 152-161

[2] HAWK WILLIAM A.(2014)Clinicopathological pattern of lymph node recurrence of papillary thyroid cancer. Implications for surgery Int J Surg 12 S194-S197

[3] CRILE GEORGE(2016)Role of prophylactic central compartment lymph node dissection in clinically N0 differentiated thyroid cancer patients: analysis of risk factors and review of modern trends World J Surg Oncol. 14 149-2029

[4] Conzo G(2016)Clinical challenges with calcitonin-negative medullary thyroid carcinoma J Cancer Res Clin Oncol 142 2023-447

[5] Mauriello C(1989)Hormone-negative, chromogranin A-positive endocrine tumors N Engl J Med 320 444-557

[6] Docimo G(2009)The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration BMJ. 339 b2700-579

[7] Gambardella C(2004)Medullary thyroid carcinoma Acta Otolaryngol 124 544-300

[8] Thomas G(2017)Clinical and pathological analysis of 19 cases of medullary thyroid carcinoma without an increase in calcitonin Exp Toxicol Pathol 69 575-349

[9] Cavallo F(2013)Prevalence and clinical spectrum of nonsecretory medullary thyroid carcinoma in a series of 839 patients with sporadic medullary thyroid carcinoma Thyroid. 23 294-152

[10] Tartaglia E(2006)Serum calcitonin negative medullary thyroid carcinoma World J Surg Oncol 4 97-899

[1] HAZARD JOHN B.(1959)MEDULLARY (SOLID) CARCINOMA OF THE THYROID—A CLINICOPATHOLOGIC ENTITY* The Journal of Clinical Endocrinology & Metabolism 19 152-161

[2] HAWK WILLIAM A.(2014)Clinicopathological pattern of lymph node recurrence of papillary thyroid cancer. Implications for surgery Int J Surg 12 S194-S197

[3] CRILE GEORGE(2016)Role of prophylactic central compartment lymph node dissection in clinically N0 differentiated thyroid cancer patients: analysis of risk factors and review of modern trends World J Surg Oncol. 14 149-2029

[4] Conzo G(2016)Clinical challenges with calcitonin-negative medullary thyroid carcinoma J Cancer Res Clin Oncol 142 2023-447

[5] Mauriello C(1989)Hormone-negative, chromogranin A-positive endocrine tumors N Engl J Med 320 444-557

[6] Docimo G(2009)The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration BMJ. 339 b2700-579

[7] Gambardella C(2004)Medullary thyroid carcinoma Acta Otolaryngol 124 544-300

[8] Thomas G(2017)Clinical and pathological analysis of 19 cases of medullary thyroid carcinoma without an increase in calcitonin Exp Toxicol Pathol 69 575-349

[9] Cavallo F(2013)Prevalence and clinical spectrum of nonsecretory medullary thyroid carcinoma in a series of 839 patients with sporadic medullary thyroid carcinoma Thyroid. 23 294-152

[10] Tartaglia E(2006)Serum calcitonin negative medullary thyroid carcinoma World J Surg Oncol 4 97-899